Home/Supreme Court/Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S

565 U.S. 1012
Procedural entryThis page is a short order in Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S. Read the opinion of the Court — 132 S. Ct. 1670 →
Supreme Court of the United States·Decided November 7, 2011·No. No. 10-844·Published

Opinion

C. A. 9th Cir. [Certiorari granted, 564 U. S. 1035.] Further consideration of respondent’s motion to dismiss as moot deferred to hearing of the case on the merits.

Free access — add to your briefcase to read the full text and ask questions with AI

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 565 U.S. 1012 (2011).

565 U.S. 1012 (Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.